The FDA granted satralizumab priority review for MOGAD after phase 3 findings showed a 68% reduction in relapse risk versus placebo.

Amélie Lothe, PhD, discusses findings showing early, sustained benefits of fenfluramine treatment for patients with Lennox-Gastaut syndrome.

FDA approved levacetylleucine (Aqneursa) for ataxia in ataxia-telangiectasia, the first therapy for the disease, in patients 15 kg or heavier.

FDA approved apitegromab-mstn (Isembyld) for SMA in patients 2 years and up, based on phase 3 data showing added motor gains with SMN2 therapy.

Stephen Bondi, JD, MD, FAAP, discusses pediatric malpractice risks and the importance of relationships and communication when adverse events occur.

At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.

In national emergency department data from 2005 to 2024, fractures were the most common pediatric e-bike injury, and e-bikes had the second-highest admission rate.

An updated AAP policy statement renews the call to ban raw milk sales, citing pathogen risks to children and pregnant people and an emerging H5N1 concern.